SCHEMBL21753361

SCHEMBL21753361

Cc1cc(C=O)ccc1-c1cccnc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.41
▸ ALDH1A3 P47895 2/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.39
▸ MKNK2 Q9HBH9 1/20 0.39
▸ TDO2 P48775 1/20 0.38
▸ VHL P40337 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ CCR1 P32246 1/20 0.37
▸ CCR8 P51685 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ FABP1 P07148 1/20 0.36
▸ ELANE P08246 1/20 0.36
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ CYP2A6 P11509 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18753445 0.82 CCR1 (0.46) ALDH1A1SMN1; SMN2CCR1CCR8KDM4E
SCHEMBL19925346 0.78 MKNK1 (0.57) ALDH1A1MKNK1MKNK2VHLSMN1; SMN2
SCHEMBL15730529 0.78 ALDH1A1 (0.44) ALDH1A1MKNK1MKNK2TDO2VHL
SCHEMBL4725122 0.77 KDM4E (0.44) ALDH1A1ALDH1A3SMN1; SMN2CCR1CCR8
SCHEMBL15730170 0.76 TDO2 (0.56) ALDH1A1MKNK1MKNK2TDO2VHL
SCHEMBL19390554 0.75 ESR2 (0.50) ALDH1A1MKNK1MKNK2TDO2
SCHEMBL3421959 0.74 MKNK1 (0.52) MKNK1MKNK2TDO2VHLSMN1; SMN2
SCHEMBL31469002 0.74 MKNK1 (0.52) MKNK1MKNK2TDO2VHLSMN1; SMN2
SCHEMBL13652318 0.73 RAB9A (0.46) ALDH1A1ALDH1A3SMN1; SMN2KDM4ECYP2A6
SCHEMBL21753295 0.73 ALDH1A3 (0.42) ALDH1A1ALDH1A3KDM4EPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 — — US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 — — US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 — — US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 — — US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 — — WO disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP ALDH1A1 1182/4885ALDH1A3 554/4885MKNK1 4094/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP ALDH1A1 1170/4885ALDH1A3 538/4885MKNK1 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback